Development of Macozinone for TB treatment: An Update
Source abstract
Abstract
Macozinone, a piperazine-benzothiazinone PBTZ169, is currently undergoing Phase 1/2 clinical studies for the treatment of tuberculosis (TB). In this review we summarize the key findings that led to the development of this compound and to identification of its target, decaprenylphospohoryl ribose oxidase DprE1, which is involved in the synthesis of the essential arabinan polymers of the cell wall in a TB pathogen, Mycobacterium tuberculosis. We present the results of the pilot clinical studies, which raise optimism regarding its further development towards more efficient TB drug regimens.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Tuberculosis Research and Epidemiology · Cancer therapeutics and mechanisms · Mycobacterium research and diagnosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Federal Research Center “Fundamentals of Biotechnology RAS”, Leninsky prospect 33, bld. 2, 119071 Moscow, Russia
Department of Biochemistry, Faculty of Natural Sciences, Comenius University in Bratislava, Mlynská dolina, Ilkovičova 6, 84215 Bratislava, Slovakia
Funding
Slovak Research and Development Agency
References (41)
Show source-provided references
1. Chapter 11. Tuberculosis
2. New insights into TB physiology suggest untapped therapeutic opportunities10.1111/imr.12267 ↗
3. (2019). Global TB Report 2019, WHO. Available online: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1.
4. Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies10.1016/S1473-3099(18)30110-5 ↗
5. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis10.1126/science.1106753 ↗
6. Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., and Komatsu, M. (2006). OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 3.10.1371/journal.pmed.0030466 ↗
7. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis10.1038/35016103 ↗
8. (2020, February 20). WGND Global TB Drug Pipeline. Available online: https://www.newtbdrugs.org/pipeline/clinical.
9. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis10.1126/science.1171583 ↗
10. Makarov, V., and Moellmann, U. (2003). New Dithiocarbamate Derivatives, Useful as Antibacterial Agents, for Treating e.g., Tuberculosis and Infections Caused by Mycobacteria and Staphylococci. (WO2003042186-A), U.S. Patent.
11. Environmental and pharmaceutical analysis of dithiocarbamates10.1016/j.aca.2006.09.022 ↗
12. Synthesis and antileprosy activity of some dialkyldithiocarbamates10.1093/jac/dkl095 ↗
13. Makarov, V.A., Cole, S.T., and Moellmann, U. (2007). New Benzothiazinone Derivatives Useful for the Treatment of Tuberculosis Infection or Leprosy Infection in Mammals. (WO2007134625-A1), U.S. Patent.
14. Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose10.1128/JB.187.23.8020-8025.2005 ↗
15. Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria10.1016/S0021-9258(17)31657-5 ↗
16. Hatfull, G.F., and Jacobs, W.R. (2000). Genetics of Cell Wall Biosythesis. Molecular Genetics of Mycobacteria, ASM Press.
17. Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-beta-D-ribose 2’-epimerase DprE1 of Mycobacterium tuberculosis10.1021/ja106357w ↗
18. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-beta-D-ribofuranose 2’-oxidase DprE110.1021/ja211042r ↗
19. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis10.1126/scitranslmed.3004395 ↗
20. Towards a new combination therapy for tuberculosis with next generation benzothiazinones10.1002/emmm.201303575 ↗
21. (2020, February 24). Innovative Medicines for Tuberculosis. Available online: http://im4tb.org.
22. The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug Macozinone (PBTZ169)10.26442/00403660.2020.03.000621 ↗
23. (2020, February 25). Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-Vivo Antitubercular Activity of PBTZ169 Formulation, Available online: https://clinicaltrials.gov/ct2/show/NCT03423030.
24. (2020, February 25). Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing, Available online: https://clinicaltrials.gov/ct2/show/NCT03776500.
25. (2020, February 25). Phase 1 Study of PBTZ169, Available online: https://clinicaltrials.gov/ct2/show/NCT03036163.
26. (2020, February 25). Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169, Available online: https://clinicaltrials.gov/ct2/show/study/NCT04150224.
27. (2020, February 25). Phase 2a Study of PBTZ169, Available online: https://clinicaltrials.gov/ct2/show/NCT03334734.
28. (2020, February 25). WHO Drug Information Volume 32, N° 3. Available online: https://www.who.int/medicines/publications/druginformation/issues/DrugInformation2018_Vol32-3/en/.
29. Piton, J., Vocat, A., Lupien, A., Foo, C.S., Riabova, O., Makarov, V., and Cole, S.T. (2018). Structure-Based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrob. Agents Chemot., 62.10.1128/AAC.00681-18 ↗
30. Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone macozinone (PBTZ169)10.1128/AAC.00840-18 ↗
31. Spaggiari, D., Desfontaine, V., Cruchon, S., Guinchard, S., Vocat, A., Blattes, E., Pitteloud, J., Ciullini, L., Bardinet, C., and Ivanyuk, A. (2019). Development and validation of a multiplex UHPLC-MS/MS method for the determination of the investigational antibiotic against multi-resistant tuberculosis macozinone (PBTZ169) and five active metabolites in human plasma. PLoS ONE, 14.10.1371/journal.pone.0217139 ↗
32. Degiacomi, G., Belardinelli, J.M., Pasca, M.R., De Rossi, E., Riccardi, G., and Chiarelli, L.R. (2020). Promiscuous targets for antitubercular drug discovery: The paradigm of DprE1 and MmpL3. Appl. Sci., 10.10.3390/app10020623 ↗
33. Tuberculosis drug discovery in the post-post-genomic era10.1002/emmm.201201772 ↗
34. DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization10.1021/acschembio.5b00237 ↗
35. (2020, February 25). A Single Ascending Dose Study of BTZ043, Available online: https://clinicaltrials.gov/ct2/show/NCT03590600.
36. (2020, February 25). BTZ-043—Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA), Available online: https://clinicaltrials.gov/ct2/show/NCT04044001.
37. 1,4-azaindole, a potential drug candidate for treatment of tuberculosis10.1128/AAC.03233-14 ↗
38. (2020, February 25). A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371, Available online: https://clinicaltrials.gov/ct2/show/NCT03199339.
39. (2020, February 25). Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis, Available online: https://clinicaltrials.gov/ct2/show/NCT04176250.
40. (2020, February 25). A Phase 1/2 Trial of Multiple oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis, Available online: https://clinicaltrials.gov/ct2/show/NCT03678688.
41. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis10.1128/AAC.00395-15 ↗